Leerink Partners维持礼来(NYSE: LLY)股票"跑赢大市"评级，目标价保持在$990.00不变。该公司在预期礼来第三季度业绩时调整了其财务模型。

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

Tirzepatide injection (Zepbound, Mounjaro) is officially off the FDA's drug shortage list, meaning compounders can no longer prepare and dispense the drug.